Rivaroxaban is associated with fewer major adverse cardiac events (MACE) and major adverse limb events (MALE) than warfarin in patients with non-valvular atrial fibrillation and comorbid type 2 diabetes, a study shows. A retrospective claims analysis in the US of more than 10,000 patients on rivaroxaban and almost 14,000 warfarin users found rivaroxaban was associated ...
AF and diabetes: DOAC better than warfarin for preventing cardiac events
By Mardi Chapman
8 Jul 2019